top of page
  • sicklecellsuffolk

EXA-CEL/CASGEVY - a gene editing therapy

Updated: May 12

The MHRA (The Medicines and Healthcare products Regulatory Agency) approved the safety of this treatment in November 2023, offering hope and optimism to the sickle cell community. But on the 14th March 2024, NICE published a draft decision NOT to recommend exa-cel/casgevy therapy for NHS funding, and opened up a consultation process. The deadline was on 11th April 2024.

Sickle cell patients, their families, advocacy groups, The Anthony Nolan project and The Sickle Cell Society were some of the groups who responded. 

On the 8th May 2024, NICE will review the consultations and have a second committee reading. The final publication will be on the 17th July 2024.

7 views0 comments

Recent Posts

See All

NICE recommendation of sickle cell treatment voxelotor

Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE in final draft guidance. Voxelotor treats haemolytic anaemia caused by sickle cell disease (SCD) and

The Infected Blood Inquiry report

The Infected Blood Inquiry report was released on the 21st May 2024. It was established to examine the circumstances in which men, women and children were given infected blood and infected blood produ


bottom of page